Asialoglycoprotein receptor-targeted superparamagnetic iron oxide nanoparticles

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Hepatology

Background:

• Superparamagnetic iron oxide (SPIO) nanoparticles are utilized in MRI and drug delivery.
• Functionalization of SPIO nanoparticles can impart targeting capabilities for specific cell types.

Purpose of the Study:

• To prepare and characterize amino-functionalized SPIO (ASPIO) and lactose-derivatized galactose-terminal-ASPIO (Gal-ASPIO).
• To evaluate the targeted binding of Gal-ASPIO to asialoglycoprotein receptor (ASGPR)-expressing hepatocytes.

Main Methods:

• Synthesis of ASPIO nanoparticles with controlled sizes.
• Derivatization of ASPIO with galactose to create Gal-ASPIO.
• In vitro cell binding assays using HepG2 (ASGPR-positive) and 143B (ASGPR-negative) cells.
• LD50 determination for Gal-ASPIO toxicity assessment.

Main Results:

• Two batches of ASPIO were prepared with average sizes of 61 nm and 127 nm.
• Lactosylation increased particle sizes to 278-337 nm.
• Gal-ASPIO-278 demonstrated specific binding to HepG2 cells, mediated by ASGPR.
• NAcASPIO-302 and Gal-ASPIO/NAcASPIO with 143B cells showed no binding.

Conclusions:

• Galactose-terminal functionalization enables targeted delivery of SPIO nanoparticles to ASGPR-expressing cells.
• Gal-ASPIO shows potential as a targeted ligand for hepatocytes in vivo.
• The study validates ASGPR-mediated binding for targeted nanoparticle applications.